Towa Pharmaceutical Co., Ltd.
4553.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.05 | -0.35 | -0.16 | 0.01 |
| FCF Yield | -0.15% | 1.03% | 8.25% | -8.05% |
| EV / EBITDA | 23.28 | 33.48 | 34.20 | 21.04 |
| Quality | ||||
| ROIC | 0.89% | 0.80% | 1.10% | 1.43% |
| Gross Margin | 36.02% | 36.34% | 36.42% | 36.73% |
| Cash Conversion Ratio | 1.44 | 2.34 | 4.06 | -0.37 |
| Growth | ||||
| Revenue 3-Year CAGR | 5.71% | 6.34% | 7.52% | 11.98% |
| Free Cash Flow Growth | -114.75% | -86.10% | 181.80% | -415.17% |
| Safety | ||||
| Net Debt / EBITDA | 13.09 | 19.40 | 20.05 | 11.37 |
| Interest Coverage | 8.60 | 9.64 | 9.96 | 20.98 |
| Efficiency | ||||
| Inventory Turnover | 0.35 | 0.37 | 0.39 | 0.41 |
| Cash Conversion Cycle | 299.12 | 285.87 | 266.07 | 246.26 |